The global Infectious Disease Molecular Diagnostics Market was valued at around US$ 34 billion in 2021. With a projected CAGR of 4.2% for the next ten years, the market is likely to reach a valuation of nearly US$ 53 billion by the end of 2032. Developers are increasingly relying on scientific developments from a variety of fields rather than the traditional methods that required the culture of the pathogens. Molecular diagnostics is one of the fields in infectious Disease identification that is expanding the fastest.
| Report Attributes | Details |
|---|---|
| Infectious Disease Molecular Diagnostics Market Size (2021A) | US$ 34.0 billion |
| Estimated Market Value (2022E) | US$ 35 billion |
| Forecasted Market Value (2032F) | US$ 53 billion |
| Global Market Growth Rate (2022 to 2032) | 4.2% CAGR |
| United States Growth Rate (2022 to 2032) | 4.3% CAGR |
| Key Companies Covered |
|
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global market for the Infectious Disease Molecular Diagnostics Market expanded at a CAGR of 3.8% over the last four years (2017 to 2021). Future Market Insights’ analysis reveals that in 2022 revenue through the market is estimated at US$ 39.5 billion. With an absolute dollar opportunity of US$ 18 billion from 2022 to 2032, the market is projected to reach a valuation of US$ 53 billion by 2032.
The USA will continue to be the largest consumer of the Infectious Disease Molecular Diagnostics Market throughout the analysis period accounting for over US$ 5.8 billion absolute dollar opportunity in the coming 10-year period
Global outbreaks of deadly infectious diseases caused by pathogenic microorganisms have threatened public health worldwide and significantly motivated researchers to develop rapid and accurate detection methods for pathogens. Culture-based techniques are considered gold standards for pathogen detection globally. However, the long result time associated with these techniques due to overnight culturing and limited pathogen isolation has slowed their demand to a certain extent. Over the past several years, innovations in molecular diagnostic technology and their use have fundamentally altered the ability to handle infectious diseases. It provides quicker and more reliable results at 30% less cost to the customers.
Although still in its infancy, pharmacogenomics has the potential to grow into a rich industry as demand for tailored medication rises. As the driving force behind the transition to personalized medicine, many pharmaceutical companies are assessing revenue models based on molecular diagnostics for pharmacogenomics testing.
Principal Consultant
One of the key factors limiting the growth of the infectious disease molecular diagnostics market is inadequate reimbursements. The hurdles to getting Medicare insurance to pay for diagnostic tests are a significant concern for diagnostic organizations. In 2018, Medicare in the USA tightened constraints on I.V.D. diagnostic claims, which affected molecular diagnostic tests in particular. These molecular pathology tests might be billed using unlisted medical codes rather than the American Medical Association's Current Procedural Terminology (CPT) numbers. Medicare Administrative Contractors (MACs) set the allowable cost amount for the billing locality in these cases.
The entirety of the clinical lab will gradually be expected to execute molecular diagnostics testing on a regular basis. Venture capitalists, who formerly preferred not to make investments in this area, will progressively grow more enthusiastic about investing in molecular diagnostic businesses as the field of molecular diagnostics progresses.
The American Cancer Society estimates that there will be 1.7 million new instances of cancer in the US this year and more than 606 thousand cancer-related deaths. Therefore, it is predicted that over the forecast period, the demand for molecular diagnostics would expand due to the rising incidence of cancer and increased public awareness of the importance of early cancer detection. The development and global distribution agreement for molecular testing in Mexico to find new sexually-transmitted infections were announced by Becton Dickinson and Euroclone in February 2019. The market is projected to expand in the future due to rising diseases and innovation in North America.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The USA will account for over US$ 16.9 billion of the global market by 2032. 6 out of 10 of America's adults have a chronic disease, and 4 out of 10 people have two or more diseases. , as of January 2021, according to a report made public by the National Center for Chronic Disease Prevention and Health Promotion. The US FDA had received emergency use authorization requests from Becton, Dickinson, and Company, and BioGX Inc. for novel diagnostic tests, the two businesses announced in March 2020.
The market in the UK is expected to reach US$ 2.2 billion, growing from US$ 1.5 billion in 2021. The market in the country is projected to expand at a CAGR of 3.5% from 2022 to 2032, and prosper with an absolute dollar opportunity of US$ 644 million.
The market in Japan is expected to gross an absolute dollar opportunity of US$ 981 million from 2022 to 2032. During this period, the market is projected to register a CAGR of 5.9% to reach a market size of US$ 2.3 billion by 2032.
The market in South Korea is expected to gross an absolute dollar opportunity of US$ 400 million from 2022 to 2032. The market is likely to reach a valuation of US$ 1.1 billion by 2032.
The Polymerase Chain Reaction (PCR) segment account for over 30% of the technology category of the global Infectious Disease Molecular Diagnostics Market. The market growth from 2017 to 2021 was estimated at 4.4% CAGR. A qualitative outcome of a PCR investigation may be required for the detection of genetic polymorphisms, inherited disorders, somatic mutations, including cancer, and the presence of viral or microbial infections.
Quantitative PCR is increasingly needed, for instance, to assess a pathogen's titer, the quantity of infected or altered cells in a tissue, and the concentration of particular mRNAs. PCR has several uses in medicine, including tissue typing for organ and tissue transplants. Commercially, HLA DQa locus analysis kits are currently readily available. The application of PCR for forensic purposes is associated with this application. The PCR can use this area, in particular, to take advantage of its extreme sensitivity.
At present, many diagnostics firms that were under-represented in this area have sought partners or acquisitions to gain exposure, reflecting the growing interest in personalized medicine. The key companies operating in the market include F. Hoffmann-La Roche Ltd., Hologic, Inc., Thermo Fisher Scientific, Inc., PerkinElmer, Inc., Abbott Laboratories, bioMérieux SA, QIAGEN N.V., Myriad Genetics, Inc., Siemens Healthineers AG, Danaher Corporation, Illumina, Inc., Becton Dickinson and Company, Grifols, S.A., Quidel Corporation, Agilent Technologies, Inc., DiaSorin S.p.a. (Italy), Exact Sciences Corporation, Genetic Signatures, MDx Health, Biocartis NV, TBG Diagnostics Limited, HTG Molecular Diagnostics, Inc., Vela Diagnostics, Amoy Diagnostics Co., Ltd., ELITechGroup, Molbio Diagnostics Pvt. Ltd., Savyon Diagnostics, Abacus Diagnostica Oy, and geneOmbio Technologies Pvt. Ltd.
Some of the recent developments by key providers of Infectious Disease Molecular Diagnostics are as follows:
Similarly, recent developments related to companies manufacturing infectious disease molecular diagnostics kits have been tracked by the team at Future Market Insights, which is available in the full report.
The global Infectious Disease Molecular Diagnostics Market was valued at US$ 34 billion in 2021.
The Infectious Disease Infectious Disease Molecular Diagnostics Market is set to witness a growth rate of 4.2% over the forecast period and be valued at US$ 53 billion by 2032.
The Infectious Disease Infectious Disease Molecular Diagnostics Market expanded by 3.7% from 2017 through 2021.
The key players BD, BioMérieux SA, Bio-Rad Laboratories Inc., Abbott, and Agilent Technologies Inc. are shaping the Infectious Disease Molecular Diagnostics Market.
United States, United Kingdom, China, Japan, and South Korea are expected to drive the most sales growth in the Infectious Disease Molecular Diagnostics Market.
1. Executive Summary | Infectious Disease Molecular Diagnostics Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. Value Chain Analysis
3.5.1. Profit Margin Analysis
3.5.2. Service Providers
3.6. PESTLE and Porter’s Analysis
3.7. Regulatory Landscape
3.7.1. By Key Regions
3.7.2. By Key Countries
3.8. Regional Parent Market Outlook
4. Global Market Analysis 2017 to 2021 and Forecast, 2022 to 2032
4.1. Historical Market Size Value (US$ billion) Analysis, 2017 to 2021
4.2. Current and Future Market Size Value (US$ billion) Projections, 2022 to 2032
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Application
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ billion) Analysis By Application, 2017 to 2021
5.3. Current and Future Market Size Value (US$ billion) Analysis and Forecast By Application, 2022 to 2032
5.3.1. Oncology
5.3.1.1. Breast Cancer
5.3.1.2. Prostate Cancer
5.3.1.3. Colorectal Cancer
5.3.1.4. Cervical Cancer
5.3.1.5. Kidney Cancer
5.3.1.6. Liver Cancer
5.3.1.7. Blood Cancer
5.3.1.8. Lung Cancer
5.3.1.9. Other Cancer
5.3.2. Infectious Diseases
5.3.2.1. Methicillin-resistant Staphylococcus Aureus (MRSA)
5.3.2.2. Clostridium Difficile
5.3.2.3. Vancomycin-resistant Enterococci (VRE)
5.3.2.4. Carbapenem-resistant Bacteria
5.3.2.5. Other Infectious Diseases
5.3.3. Genetic Testing
5.3.3.1. Newborn Screening
5.3.3.2. Predictive and Presymptomatic Testing
5.3.3.3. Other Genetic Testing
5.3.4. Pharmacogenomics
5.3.5. Neurological Disease
5.3.6. Cardiovascular Disease
5.4. Y-o-Y Growth Trend Analysis By Application, 2017 to 2021
5.5. Absolute $ Opportunity Analysis By Application, 2022 to 2032
6. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Product Type
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ billion) Analysis By Product Type, 2017 to 2021
6.3. Current and Future Market Size Value (US$ billion) Analysis and Forecast By Product Type, 2022 to 2032
6.3.1. Instruments
6.3.2. Reagents
6.3.3. Other Product Types
6.4. Y-o-Y Growth Trend Analysis By Product Type, 2017 to 2021
6.5. Absolute $ Opportunity Analysis By Product Type, 2022 to 2032
7. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Test Location
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ billion) Analysis By Test Location, 2017 to 2021
7.3. Current and Future Market Size Value (US$ billion) Analysis and Forecast By Test Location, 2022 to 2032
7.3.1. Point-of-Care
7.3.2. Self-test or Over the Counter
7.3.3. Central Laboratories
7.4. Y-o-Y Growth Trend Analysis By Test Location, 2017 to 2021
7.5. Absolute $ Opportunity Analysis By Test Location, 2022 to 2032
8. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Technology
8.1. Introduction / Key Findings
8.2. Historical Market Size Value (US$ billion) Analysis By Technology, 2017 to 2021
8.3. Current and Future Market Size Value (US$ billion) Analysis and Forecast By Technology, 2022 to 2032
8.3.1. Polymerase Chain Reaction (PCR)
8.3.2. In Situ Hybridization (ISH)
8.3.3. Isothermal Nucleic Acid Amplification Technology (INAAT)
8.3.4. Chips and Microarrays
8.3.5. Mass Spectrometry
8.3.6. Sequencing
8.3.7. Transcription Mediated Amplification (TMA)
8.3.8. Other Technologies
8.4. Y-o-Y Growth Trend Analysis By Technology, 2017 to 2021
8.5. Absolute $ Opportunity Analysis By Technology, 2022 to 2032
9. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Region
9.1. Introduction
9.2. Historical Market Size Value (US$ billion) Analysis By Region, 2017 to 2021
9.3. Current Market Size Value (US$ billion) Analysis and Forecast By Region, 2022 to 2032
9.3.1. North America
9.3.2. Latin America
9.3.3. Europe
9.3.4. Asia Pacific
9.3.5. Middle East and Africa (MEA)
9.4. Market Attractiveness Analysis By Region
10. North America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
10.1. Historical Market Size Value (US$ billion) Trend Analysis By Market Taxonomy, 2017 to 2021
10.2. Market Size Value (US$ billion) Forecast By Market Taxonomy, 2022 to 2032
10.2.1. By Country
10.2.1.1. United States of America
10.2.1.2. Canada
10.2.2. By Application
10.2.3. By Product Type
10.2.4. By Test Location
10.2.5. By Technology
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Application
10.3.3. By Product Type
10.3.4. By Test Location
10.3.5. By Technology
10.4. Key Takeaways
11. Latin America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
11.1. Historical Market Size Value (US$ billion) Trend Analysis By Market Taxonomy, 2017 to 2021
11.2. Market Size Value (US$ billion) Forecast By Market Taxonomy, 2022 to 2032
11.2.1. By Country
11.2.1.1. Brazil
11.2.1.2. Mexico
11.2.1.3. Rest of Latin America
11.2.2. By Application
11.2.3. By Product Type
11.2.4. By Test Location
11.2.5. By Technology
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Application
11.3.3. By Product Type
11.3.4. By Test Location
11.3.5. By Technology
11.4. Key Takeaways
12. Europe Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
12.1. Historical Market Size Value (US$ billion) Trend Analysis By Market Taxonomy, 2017 to 2021
12.2. Market Size Value (US$ billion) Forecast By Market Taxonomy, 2022 to 2032
12.2.1. By Country
12.2.1.1. Germany
12.2.1.2. Italy
12.2.1.3. France
12.2.1.4. United Kingdom
12.2.1.5. Spain
12.2.1.6. Russia
12.2.1.7. Rest of Europe
12.2.2. By Application
12.2.3. By Product Type
12.2.4. By Test Location
12.2.5. By Technology
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Application
12.3.3. By Product Type
12.3.4. By Test Location
12.3.5. By Technology
12.4. Key Takeaways
13. Asia Pacific Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
13.1. Historical Market Size Value (US$ billion) Trend Analysis By Market Taxonomy, 2017 to 2021
13.2. Market Size Value (US$ billion) Forecast By Market Taxonomy, 2022 to 2032
13.2.1. By Country
13.2.1.1. China
13.2.1.2. Japan
13.2.1.3. India
13.2.1.4. South Korea
13.2.1.5. Australia
13.2.1.6. Rest of APAC
13.2.2. By Application
13.2.3. By Product Type
13.2.4. By Test Location
13.2.5. By Technology
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Application
13.3.3. By Product Type
13.3.4. By Test Location
13.3.5. By Technology
13.4. Key Takeaways
14. MEA Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
14.1. Historical Market Size Value (US$ billion) Trend Analysis By Market Taxonomy, 2017 to 2021
14.2. Market Size Value (US$ billion) Forecast By Market Taxonomy, 2022 to 2032
14.2.1. By Country
14.2.1.1. South Africa
14.2.1.2. Saudi Arabia
14.2.1.3. UAE
14.2.1.4. Israel
14.2.1.5. Rest of MEA
14.2.2. By Application
14.2.3. By Product Type
14.2.4. By Test Location
14.2.5. By Technology
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Application
14.3.3. By Product Type
14.3.4. By Test Location
14.3.5. By Technology
14.4. Key Takeaways
15. Key Countries Market Analysis
15.1. United States of America
15.1.1. Pricing Analysis
15.1.2. Market Share Analysis, 2021
15.1.2.1. By Application
15.1.2.2. By Product Type
15.1.2.3. By Test Location
15.1.2.4. By Technology
15.2. Canada
15.2.1. Pricing Analysis
15.2.2. Market Share Analysis, 2021
15.2.2.1. By Application
15.2.2.2. By Product Type
15.2.2.3. By Test Location
15.2.2.4. By Technology
15.3. Brazil
15.3.1. Pricing Analysis
15.3.2. Market Share Analysis, 2021
15.3.2.1. By Application
15.3.2.2. By Product Type
15.3.2.3. By Test Location
15.3.2.4. By Technology
15.4. Mexico
15.4.1. Pricing Analysis
15.4.2. Market Share Analysis, 2021
15.4.2.1. By Application
15.4.2.2. By Product Type
15.4.2.3. By Test Location
15.4.2.4. By Technology
15.5. Germany
15.5.1. Pricing Analysis
15.5.2. Market Share Analysis, 2021
15.5.2.1. By Application
15.5.2.2. By Product Type
15.5.2.3. By Test Location
15.5.2.4. By Technology
15.6. Italy
15.6.1. Pricing Analysis
15.6.2. Market Share Analysis, 2021
15.6.2.1. By Application
15.6.2.2. By Product Type
15.6.2.3. By Test Location
15.6.2.4. By Technology
15.7. France
15.7.1. Pricing Analysis
15.7.2. Market Share Analysis, 2021
15.7.2.1. By Application
15.7.2.2. By Product Type
15.7.2.3. By Test Location
15.7.2.4. By Technology
15.8. United Kingdom
15.8.1. Pricing Analysis
15.8.2. Market Share Analysis, 2021
15.8.2.1. By Application
15.8.2.2. By Product Type
15.8.2.3. By Test Location
15.8.2.4. By Technology
15.9. Spain
15.9.1. Pricing Analysis
15.9.2. Market Share Analysis, 2021
15.9.2.1. By Application
15.9.2.2. By Product Type
15.9.2.3. By Test Location
15.9.2.4. By Technology
15.10. Russia
15.10.1. Pricing Analysis
15.10.2. Market Share Analysis, 2021
15.10.2.1. By Application
15.10.2.2. By Product Type
15.10.2.3. By Test Location
15.10.2.4. By Technology
15.11. China
15.11.1. Pricing Analysis
15.11.2. Market Share Analysis, 2021
15.11.2.1. By Application
15.11.2.2. By Product Type
15.11.2.3. By Test Location
15.11.2.4. By Technology
15.12. Japan
15.12.1. Pricing Analysis
15.12.2. Market Share Analysis, 2021
15.12.2.1. By Application
15.12.2.2. By Product Type
15.12.2.3. By Test Location
15.12.2.4. By Technology
15.13. India
15.13.1. Pricing Analysis
15.13.2. Market Share Analysis, 2021
15.13.2.1. By Application
15.13.2.2. By Product Type
15.13.2.3. By Test Location
15.13.2.4. By Technology
15.14. South Korea
15.14.1. Pricing Analysis
15.14.2. Market Share Analysis, 2021
15.14.2.1. By Application
15.14.2.2. By Product Type
15.14.2.3. By Test Location
15.14.2.4. By Technology
15.15. Australia
15.15.1. Pricing Analysis
15.15.2. Market Share Analysis, 2021
15.15.2.1. By Application
15.15.2.2. By Product Type
15.15.2.3. By Test Location
15.15.2.4. By Technology
15.16. South Africa
15.16.1. Pricing Analysis
15.16.2. Market Share Analysis, 2021
15.16.2.1. By Application
15.16.2.2. By Product Type
15.16.2.3. By Test Location
15.16.2.4. By Technology
15.17. Saudi Arabia
15.17.1. Pricing Analysis
15.17.2. Market Share Analysis, 2021
15.17.2.1. By Application
15.17.2.2. By Product Type
15.17.2.3. By Test Location
15.17.2.4. By Technology
15.18. UAE
15.18.1. Pricing Analysis
15.18.2. Market Share Analysis, 2021
15.18.2.1. By Application
15.18.2.2. By Product Type
15.18.2.3. By Test Location
15.18.2.4. By Technology
15.19. Israel
15.19.1. Pricing Analysis
15.19.2. Market Share Analysis, 2021
15.19.2.1. By Application
15.19.2.2. By Product Type
15.19.2.3. By Test Location
15.19.2.4. By Technology
16. Market Structure Analysis
16.1. Competition Dashboard
16.2. Competition Benchmarking
16.3. Market Share Analysis of Top Players
16.3.1. By Regional
16.3.2. By Application
16.3.3. By Product Type
16.3.4. By Test Location
16.3.5. By Technology
17. Competition Analysis
17.1. Competition Deep Dive
17.1.1. BD
17.1.1.1. Overview
17.1.1.2. Product Portfolio
17.1.1.3. Profitability by Market Segments
17.1.1.4. Sales Footprint
17.1.1.5. Strategy Overview
17.1.1.5.1. Marketing Strategy
17.1.1.5.2. Product Strategy
17.1.1.5.3. Channel Strategy
17.1.2. BioMérieux SA
17.1.2.1. Overview
17.1.2.2. Product Portfolio
17.1.2.3. Profitability by Market Segments
17.1.2.4. Sales Footprint
17.1.2.5. Strategy Overview
17.1.2.5.1. Marketing Strategy
17.1.2.5.2. Product Strategy
17.1.2.5.3. Channel Strategy
17.1.3. Bio-Rad Laboratories Inc
17.1.3.1. Overview
17.1.3.2. Product Portfolio
17.1.3.3. Profitability by Market Segments
17.1.3.4. Sales Footprint
17.1.3.5. Strategy Overview
17.1.3.5.1. Marketing Strategy
17.1.3.5.2. Product Strategy
17.1.3.5.3. Channel Strategy
17.1.4. Abbott
17.1.4.1. Overview
17.1.4.2. Product Portfolio
17.1.4.3. Profitability by Market Segments
17.1.4.4. Sales Footprint
17.1.4.5. Strategy Overview
17.1.4.5.1. Marketing Strategy
17.1.4.5.2. Product Strategy
17.1.4.5.3. Channel Strategy
17.1.5. Agilent Technologies, Inc.
17.1.5.1. Overview
17.1.5.2. Product Portfolio
17.1.5.3. Profitability by Market Segments
17.1.5.4. Sales Footprint
17.1.5.5. Strategy Overview
17.1.5.5.1. Marketing Strategy
17.1.5.5.2. Product Strategy
17.1.5.5.3. Channel Strategy
17.1.6. Danaher
17.1.6.1. Overview
17.1.6.2. Product Portfolio
17.1.6.3. Profitability by Market Segments
17.1.6.4. Sales Footprint
17.1.6.5. Strategy Overview
17.1.6.5.1. Marketing Strategy
17.1.6.5.2. Product Strategy
17.1.6.5.3. Channel Strategy
17.1.7. Hologic Inc
17.1.7.1. Overview
17.1.7.2. Product Portfolio
17.1.7.3. Profitability by Market Segments
17.1.7.4. Sales Footprint
17.1.7.5. Strategy Overview
17.1.7.5.1. Marketing Strategy
17.1.7.5.2. Product Strategy
17.1.7.5.3. Channel Strategy
17.1.8. IlluminaInc
17.1.8.1. Overview
17.1.8.2. Product Portfolio
17.1.8.3. Profitability by Market Segments
17.1.8.4. Sales Footprint
17.1.8.5. Strategy Overview
17.1.8.5.1. Marketing Strategy
17.1.8.5.2. Product Strategy
17.1.8.5.3. Channel Strategy
17.1.9. Johnson & Johnson Services Inc
17.1.9.1. Overview
17.1.9.2. Product Portfolio
17.1.9.3. Profitability by Market Segments
17.1.9.4. Sales Footprint
17.1.9.5. Strategy Overview
17.1.9.5.1. Marketing Strategy
17.1.9.5.2. Product Strategy
17.1.9.5.3. Channel Strategy
17.1.10. GrifolsS.A.
17.1.10.1. Overview
17.1.10.2. Product Portfolio
17.1.10.3. Profitability by Market Segments
17.1.10.4. Sales Footprint
17.1.10.5. Strategy Overview
17.1.10.5.1. Marketing Strategy
17.1.10.5.2. Product Strategy
17.1.10.5.3. Channel Strategy
17.1.11. QIAGEN
17.1.11.1. Overview
17.1.11.2. Product Portfolio
17.1.11.3. Profitability by Market Segments
17.1.11.4. Sales Footprint
17.1.11.5. Strategy Overview
17.1.11.5.1. Marketing Strategy
17.1.11.5.2. Product Strategy
17.1.11.5.3. Channel Strategy
17.1.12. F. Hoffmann-La RocheLtd
17.1.12.1. Overview
17.1.12.2. Product Portfolio
17.1.12.3. Profitability by Market Segments
17.1.12.4. Sales Footprint
17.1.12.5. Strategy Overview
17.1.12.5.1. Marketing Strategy
17.1.12.5.2. Product Strategy
17.1.12.5.3. Channel Strategy
17.1.13. Siemens Healthineers AG
17.1.13.1. Overview
17.1.13.2. Product Portfolio
17.1.13.3. Profitability by Market Segments
17.1.13.4. Sales Footprint
17.1.13.5. Strategy Overview
17.1.13.5.1. Marketing Strategy
17.1.13.5.2. Product Strategy
17.1.13.5.3. Channel Strategy
18. Assumptions & Acronyms Used
19. Research Methodology
Explore Healthcare Insights
View Reports
Infectious Disease Molecular Diagnostics Market
